KRAS G12V ONCOLOGY
Redefining survival
in KRAS-driven cancers
Pancreatic · Colorectal · Lung · Liver
First-in-class intracellular oncology · Phase I ready
THE PROBLEM
An oncogenic driver no therapy can reach
ZERO
Approved intracellular biologics targeting KRAS. In any cancer. Anywhere in the world.
KRAS G12V sits inside the cell. Every approved therapy operates outside it. Over four decades of drug development have failed to reach this target with a biologic.
It drives persistent oncogenic signalling that defeats chemotherapy, immunotherapy, and targeted small molecules — across pancreatic, colorectal, lung, endometrial, and ovarian cancers.
The barrier is not the target — it is access.
OUR APPROACH
Precision intracellular targeting
Our lead programme uses a natural lipoprotein carrier to deliver an antibody directly to KRAS G12V inside the cancer cell.
PIPELINE
Lead programme
COMPANY
A focused oncology company
PanKras Therapeutics is a clinical-stage oncology company developing first-in-class intracellular biologics for KRAS G12V-driven cancers.
The company holds exclusive rights to use a proprietary intracellular delivery technology for KRAS G12V oncology across four tumour types, secured via license from its parent holding company.
PanKras is headquartered at the Malta Life Sciences Park.